Xiao Linlin, Lin Qiang, Hu Mengzhu, Wang Yi, Hui Zhouguang, Wu Fengpeng, Wang Jun
Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu, China.
Thorac Cancer. 2022 Apr;13(8):1193-1198. doi: 10.1111/1759-7714.14384. Epub 2022 Mar 15.
A previous study demonstrated that intracranial tumor volume had some correlation with gastrointestinal cancer patients' outcome. The aim of this study was to analyze patients with esophageal carcinoma (EC) and brain metastases to investigate if intracranial tumor volume would be a predictor of these patients' survival.
A total of 52 patients with brain metastases from esophageal squamous cell carcinoma or esophageal adenocarcinoma were retrospectively reviewed. Patients without images of brain metastases in the hospital information system were eliminated.
The median follow-up time duration was 8.4 months (interquartile range 4.0-15.2). The median overall survival (OS) from time of brain metastases diagnosis was 8.0 months for all cases. Median OS of patients with small and large cumulative intracranial tumor volume (CITV) (<6.65 cm , ≥6.65 cm ) was 11.23 and 7.4 months, respectively. Median OS of patients with large and small largest intracranial tumor volume (LITV) (≥7.75 cm , <7.75 cm ) was 6.4 and 10.6 months, respectively. Univariate analysis demonstrated that CITV (hazard ratio [HR] 1.255, 95% confidence interval [CI] 0.673-2.342, p = 0.475) or LITV (HR 1.037, 95% CI 0.570-1.887, p = 0.904) was not significantly associated with improved OS. Multivariate analysis demonstrated that CITV and LITV were not significantly associated with improved OS.
EC patients with small intracranial tumor volume may have longer OS than those with large intracranial tumor volume, but this difference did not reach statistical difference. Future studies with a larger sample size may validate the correlation of intracranial tumor volume and patient survival.
先前的一项研究表明,颅内肿瘤体积与胃肠道癌患者的预后存在一定相关性。本研究旨在分析食管癌(EC)伴脑转移患者,以探讨颅内肿瘤体积是否为这些患者生存的预测指标。
回顾性分析了52例食管鳞状细胞癌或食管腺癌脑转移患者。排除医院信息系统中无脑转移影像的患者。
中位随访时间为8.4个月(四分位间距4.0 - 15.2)。所有病例自脑转移诊断起的中位总生存期(OS)为8.0个月。累积颅内肿瘤体积(CITV)小(<6.65 cm³)和大(≥6.65 cm³)的患者中位OS分别为11.23个月和7.4个月。最大颅内肿瘤体积(LITV)大(≥7.75 cm³)和小(<7.75 cm³)的患者中位OS分别为6.4个月和10.6个月。单因素分析表明,CITV(风险比[HR] 1.255,95%置信区间[CI] 0.673 - 2.342,p = 0.475)或LITV(HR 1.037,95% CI 0.570 - 1.887,p = 0.904)与OS改善无显著相关性。多因素分析表明,CITV和LITV与OS改善无显著相关性。
颅内肿瘤体积小的EC患者可能比颅内肿瘤体积大的患者OS更长,但这种差异未达到统计学差异。未来更大样本量的研究可能会验证颅内肿瘤体积与患者生存的相关性。